Effect of continuous pharmaceutical care on anticoagulation in a patient with VTE
TAN Hongyang1 WAN Jianwei2
1.Department of Pharmacy, Pudong Center for Mental Health, Shanghai 200124, China;
2.Department of Pharmacy, Zhoupu Hospital of Shanghai Pudong New District, Shanghai 201318, China
Abstract：Clinical pharmacists played active roles in the safety and effectiveness of anticoagulant therapy in a patient with VTE, by means of continuous pharmaceutical care. When the patient was hospitalized, clinical pharmacists participated in the formulation of initial therapeutic schedule and carried out pharmaceutical care. Then clinical pharmacists assisted physicians to develop individualized drug regimen, according to the anticoagulant effect and patient′s medication situation. After the patient was stable and discharged, clinical pharmacists offered regular follow-up, and assisted the physician to adjust the medication regimen again according to the patient′s follow-up situation, so that the international normalized ratio of the patient could reach the standard and maintain stability.
谭红阳1 万建伟2. 连续性药学监护改善1例VTE患者抗凝效果[J]. 中国医药导报, 2017, 14(30): 157-160.
TAN Hongyang1 WAN Jianwei2. Effect of continuous pharmaceutical care on anticoagulation in a patient with VTE. 中国医药导报, 2017, 14(30): 157-160.
[1] National Clinical Guidenline Centre（UK）.Venous thromboembolic disease： the management of venous thromboembolic diseases and the role of thrombophilia testing.[J].Thorax，2012，68（4）：2-5.
[2] Dager WE，Gulseth M P，Nutescu EA.抗凝治疗医护指南[M].师水军，吕永宁，译.北京：人民卫生出版社，2012.
[3] 李苒. CYP2C9和VK0RC1基因多态性对肺血栓栓塞症患者华法林维持剂量影响的临床研究[D].昆明：昆明医科大学，2015.
[4] 于向东，孙跃民. 新型口服抗凝药物在非瓣膜性房颤卒中预防中的应用进展[J].中国慢性病预防与控制，2015， 23（6）：455-459.
[5] 中华医学会心血管病学分会.华法林抗凝治疗的中国专家共识[J].中华内科杂志，2013，52（1）：76-82.
[6] Eikelboom JW，Hirsh J，Spencer FA，et al. Executive summary：antithrombotic therapy and prevention of thrombosis，9th ed：American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. [J]. Chest，2012，141（2）：e419S.
[7] Klok FA，Huisman MV. Assessment of bleeding risk in patients with venous thromboembolism：we are still a long way from home[J].Ned Tijdschr Geneesk，2016，160：D140.
[8] Lip GY，Frison L，Halperin JL，et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation：the HAS-BLED （hypertension，abnormal renal/liver function，stroke，bleeding history or predisposition，labile INR，elderly，drugs alcohol concomitantly score.[J].J Am Coll Cardiol，2011，57（2）：173-180.
[9] Guyatt G，Akl EA，Crowther M. Schuünemann and for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel[J]. Chest，2012， 141（Suppl 2）：7S.
[10] Luengo-Fernandez R，Yiin GS，Gray AM，et al. Population-based study of acute- and long-term care costs after stroke in patients with AF [J]. Int J Stroke，2013，8（5）：308-314.
[11] 张春来，梁颖，左万里，等.尿激酶、低分子肝素和华法林的不同联合方案治疗肺栓塞的临床研究[J].临床合理用药杂志，2011，4（14）：5-6.
[12] 郑策，梅丹.影响华法林抗凝血作用的有关因素[J].药物不良反应杂志，2007，9（4）：256-261.
[13] 郭芮彤，于锋，徐航，等.质子泵抑制剂对华法林抗凝效果影响的研究进展[J].药学与临床研究，2015（5）：479-483.
[14] 孟慧杰，石伟龙，胡永芳. 1例利福平与华法林相互作用的案例报道及文献分析[J].中国药学杂志，2015，50（6）：550-553.
[15] 况赟，孙雪 阳喜定，等.华法林定量药理学的研究进展[J].中国临床药理学与治疗学，2015，20（7）：814-821.
[16] 葛卫红.华法林抗凝治疗临床药师指导手册[M].北京：人民卫生出版社，2009.
[17] Wittkowsky AK，Nutescu EA，Blackburn J，et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting [J]. Chest，2006，130（5）：1385-1389.
[18] 黄月初，韦冬玲，韦冬蕾，等.临床护理路径在肺栓塞患者抗凝治疗及健康教育中的应用效果[J].当代护士：学术版，2015（5）：18-19.
[19] 蒋捷，谢秋芬，向倩，等.药师干预对华法林抗凝患者治疗认知度的影响研究[J].中国临床药理学杂志，2015（13）：1315-1317.
[20] 古忆. 2011美国大面积肺栓塞、深静脉血栓形成及慢性血栓栓塞性肺动脉高压治疗指南解读[J].心血管病学进展，2012，33（2）：164-167.
[21] 杨苓，张敏，方杰.房颤患者应用华法令抗凝治疗的影响因素与对策[J].中外医疗，2015，24（4）：130-132.
2017, Vol. 14 
京公网安备 11010502046598号